NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Neuronetics, Inc. (STIM) Stock Analysis

Neuronetics, Inc. (STIM) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

STIM

$2.88

+$0.16 (+5.88%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare STIM with… →

STIM Key Statistics

As of Sep 4, 2026
Trading
Open
$2.72
Previous Close
$2.72
Day's Range
2.68–2.97
52-Week Range
0.80–3.71
Volume
996.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.17
Valuation
Market Cap
$219.45M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.41
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.43
Financials (FY)
Revenue (FY)
$149.16M+99.17%
Net Income (FY)
−$39.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
−19.62%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
76.20M
1-Year Return
−12.99%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
2.12M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

STIM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+108.70%
2025−14.29%
2024−44.48%
2023−57.79%
2022+54.04%
2021−59.86%
2020+147.44%
2019−76.80%
2018 (partial year)−30.35%

As of September 4, 2026.

STIM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$149.16M−$39.00M−26.1%
2024$74.89M−$43.71M−58.4%
2023$71.35M−$30.19M−42.3%
2022$65.21M−$37.16M−57.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$149.16M$72.31M−$31.44M−$39.00M−26.1%
2024$74.89M$54.16M−$34.56M−$43.71M−58.4%
2023$71.35M$51.71M−$30.55M−$30.19M−42.3%
2022$65.21M$49.72M−$35.11M−$37.16M−57.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

STIM Valuation vs Medical Devices Median

Median of 151 stocks
MetricSTIMMedical Devices medianvs median
P/S ratio1.412.9852% below
Profit margin−19.62%−1.69%17.9 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Neuronetics, Inc. (STIM) carries a market capitalisation of $219.45M. The company sits in the Healthcare sector, in the Medical Devices industry. The company reports 658 employees.

Over the past 52 weeks the price has ranged from $0.80 to $3.71. STIM last closed at $2.88 on September 4, 2026. That is +$0.16 (+5.88%) against the previous close. The latest close sits 260% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $149.16M. Against the prior fiscal year total of $74.89M, that is a change of +99.17%. The same year closed with a net loss of $39.00M. The reported profit margin is −19.62%. That is 17.9 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −0.43.

Across the 4 fiscal years on file, revenue moves from $65.21M in 2022 to $149.16M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 1.41. On price-to-sales that is 52.46% below the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The trailing one-year price return is −12.99%. Across 5 years the annualized return works out at −17.53%. The reported beta is 1.17. Daily returns over the trailing 8 years annualize to a volatility of 97.41%.

Growth & Income

The record shows no dividend for STIM.

The strongest complete calendar year on file is 2020 at +147.44%; the weakest is 2019 at −76.80%. Of the 7 complete calendar years on file, 2 finished higher. So far in 2026 the price is +108.70%.

Peer Comparison

Neuronetics, Inc. (STIM) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Neuronetics, Inc. STIM $219.45M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Neuronetics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Neuronetics, Inc.

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Visit website →